AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30307504 — intervention group
Group type: COMPARATOR
Intervention: Tanaka equation
Number of subjects: 3270
Study 30307504 — intervention group
Group type: COMPARATOR
Intervention: Kawasaki equation
Number of subjects: 3270
Study 30307504 — intervention group
Group type: COMPARATOR
Intervention: Intersalt without potassium equation
Number of subjects: 3270
Study 30307504 — intervention group
Group type: COMPARATOR
Intervention: Intersalt with potassium equation
Number of subjects: 3270
Study 28302636 — intervention group
Group type: EXPERIMENTAL
Intervention: MR within 24 hours of admission and at discharge
Number of subjects: 200
Study 28302636 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 200
Study 25352018 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 1778
Study 25352018 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 1778
Study 25352018 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1778
Study 22290216 — intervention group
Group type: EXPERIMENTAL
Intervention: Side-to-side anastomosis
Number of subjects: 67
Study 22290216 — intervention group
Group type: COMPARATOR
Intervention: End-to-end anastomosis
Number of subjects: 67
Study 21592480 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg/day for 4 weeks
Number of subjects: 20
Study 21592480 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 20
Study 18089691 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 IU vitamin D2
Number of subjects: 0
Study 18089691 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 IU vitamin D3
Number of subjects: 0
Study 18089691 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 IU vitamin D2 plus 500 IU vitamin D3
Number of subjects: 0
Study 16565456 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple Dissemination (SD)
Number of subjects: 5849
Study 16565456 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Dissemination (ID)
Number of subjects: 5849
Study 16565456 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 5849
Study 14582689 — intervention group
Group type: EXPERIMENTAL
Intervention: Monochromatic pulsating light treatment
Number of subjects: 164
Study 14582689 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 164
Study 11078237 — intervention group
Group type: COMPARATOR
Intervention: Fenofibrate 200 mg
Number of subjects: 102
Study 11078237 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg plus Fenofibrate 200 mg
Number of subjects: 102
Study 11078237 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg plus Fenofibrate 200 mg
Number of subjects: 102
Study 8969977 — intervention group
Group type: EXPERIMENTAL
Intervention: FK506 (tacrolimus)
Number of subjects: 0
Study 8969977 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic monitoring of whole-blood FK506 levels
Number of subjects: 0
Study 1428034 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy (EST)
Number of subjects: 32
Study 1428034 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 32
Study 6366553 — intervention group
Group type: COMPARATOR
Intervention: Moderate alcohol intake (control drinking group)
Number of subjects: 24
Study 6366553 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstention from alcohol (abstention group)
Number of subjects: 24
Study 6366553 — intervention group
Group type: EXPERIMENTAL
Intervention: Resumption of drinking after abstention
Number of subjects: 24
Study 31561881 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane at 0.5 MAC
Number of subjects: 60
Study 31561881 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane at 1.0 MAC
Number of subjects: 60
Study 31561881 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane at 1.5 MAC
Number of subjects: 60
Study 29381726 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Valsalva maneuver (MVM) for 30 days
Number of subjects: 72
Study 29381726 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (NVM group)
Number of subjects: 72
Study 26771282 — intervention group
Group type: EXPERIMENTAL
Intervention: Food supplement containing forskolin, homotaurine, carnosine, folic acid, vitamins B1, B2, B6, and magnesium, 2 tablets per day for 12 months.
Number of subjects: 22
Study 26771282 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (not specified in detail).
Number of subjects: 22
Study 24631567 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS alone
Number of subjects: 9
Study 24631567 — intervention group
Group type: EXPERIMENTAL
Intervention: MP alone
Number of subjects: 9
Study 24631567 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of tDCS and MP
Number of subjects: 9
Study 24631567 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 9
Study 22271411 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam 1.875 g b.i.d. for 14 days
Number of subjects: 24
Study 22271411 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 24
Study 20306005 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive vascular care (4-monthly visits to a practice nurse monitoring cardiovascular risk factors)
Number of subjects: 3535
Study 20306005 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 3535
Study 20306005 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive vascular care
Number of subjects: 3535
Study 18925641 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (1 patient withdrew consent at 3 months)
Number of subjects: 34
Study 18925641 — intervention group
Group type: COMPARATOR
Intervention: Combination HBIG plus lamivudine
Number of subjects: 34
Study 18925641 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil
Number of subjects: 34
Study 18925641 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination adefovir/lamivudine prophylaxis
Number of subjects: 34
Study 18925641 — intervention group
Group type: COMPARATOR
Intervention: IM HBIG/lamivudine
Number of subjects: 34
Study 16208659 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 22
Study 16208659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 11863090 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus carboplatin (PC) - P 175 mg/m2 and C at AUC = 7, intravenous infusion on day 1
Number of subjects: 90
Study 11863090 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel plus gemcitabine (PG) - P 175 mg/m2 on day 1 and G 1000 mg/m2 on days 1 and 8, every 3 weeks
Number of subjects: 90
Study 10079631 — intervention group
Group type: EXPERIMENTAL
Intervention: Digora phosphor plate
Number of subjects: 130
Study 10079631 — intervention group
Group type: COMPARATOR
Intervention: Trophy RVG XL, CCD-based sensor
Number of subjects: 130
Study 10079631 — intervention group
Group type: EXPERIMENTAL
Intervention: Both systems
Number of subjects: 130
Study 7572513 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 ml gadopentetate dimeglumine
Number of subjects: 152
Study 7572513 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml gadopentetate dimeglumine
Number of subjects: 152
Study 7572513 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml gadopentetate dimeglumine
Number of subjects: 152
Study 7572513 — intervention group
Group type: COMPARATOR
Intervention: Unenhanced MR angiograms
Number of subjects: 152
Study 7572513 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced MR angiograms
Number of subjects: 152
Study 2251208 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (15 mg)
Number of subjects: 15
Study 2251208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 7011019 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily applications of a povidone-iodine solution and ointment
Number of subjects: 200
Study 7011019 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily meatal cleansing with a nonantiseptic solution of green soap and water
Number of subjects: 200
Study 7011019 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment) for povidone-iodine
Number of subjects: 200
Study 7011019 — intervention group
Group type: COMPARATOR
Intervention: Control group (no special meatal care) for green soap
Number of subjects: 200
Study 31240335 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermaplasty-assisted lipoplasty (DAL)
Number of subjects: 135
Study 31240335 — intervention group
Group type: COMPARATOR
Intervention: Standard suction-assisted lipectomy (SAL)
Number of subjects: 135
Study 31079535 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegloticase (8 mg every 2 weeks)
Number of subjects: 173
Study 31079535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study 28962046 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium butyrate capsules
Number of subjects: 60
Study 28962046 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin supplement powder
Number of subjects: 60
Study 28962046 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium butyrate + inulin
Number of subjects: 60
Study 28962046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 25040503 — intervention group
Group type: EXPERIMENTAL
Intervention: PCC/PGL patients
Number of subjects: 28
Study 23567394 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy for 12 weeks
Number of subjects: 22
Study 23567394 — intervention group
Group type: COMPARATOR
Intervention: Psychotherapy nonresponders
Number of subjects: 22
Study 21354553 — intervention group
Group type: EXPERIMENTAL
Intervention: TRACEr-RAV1
Number of subjects: 36
Study 21354553 — intervention group
Group type: EXPERIMENTAL
Intervention: TRACEr-RAV2
Number of subjects: 36
Study 21354553 — intervention group
Group type: COMPARATOR
Intervention: TRACEr-Rail
Number of subjects: 36
Study 19683825 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed-time NPH insulin
Number of subjects: 28
Study 19683825 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 28
Study 17846285 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (600 IU on alternate days)
Number of subjects: 39876
Study 17846285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39876
Study 15281501 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.125%; 0.2 mg x kg(‐1) x h(‐1))
Number of subjects: 81
Study 15281501 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine (0.125%; 0.2 mg x kg(‐1) x h(‐1))
Number of subjects: 81
Study 15281501 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (0.125%; 0.2 mg x kg(‐1) x h(‐1))
Number of subjects: 81
Study 15281501 — intervention group
Group type: COMPARATOR
Intervention: All groups (Bupivacaine, Levobupivacaine, Ropivacaine)
Number of subjects: 81
Study 11157017 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermography catheter method to detect temperature differences (Delta T) between solid tumors and normal areas.
Number of subjects: 20
Study 9990415 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene 0.1% gel
Number of subjects: 30
Study 9990415 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene 0.1% cream
Number of subjects: 30
Study 9990415 — intervention group
Group type: COMPARATOR
Intervention: Tretinoin 0.05% cream
Number of subjects: 30
Study 9990415 — intervention group
Group type: COMPARATOR
Intervention: Tretinoin 0.1% cream
Number of subjects: 30
Study 9990415 — intervention group
Group type: COMPARATOR
Intervention: Tretinoin formulations (0.05% and 0.1%)
Number of subjects: 30
Study 9990415 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene 0.1% gel and cream
Number of subjects: 30
Study 7921299 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter addressed to parents (parent group)
Number of subjects: 449
Study 7921299 — intervention group
Group type: COMPARATOR
Intervention: Letter addressed to adolescents (adolescent group)
Number of subjects: 449
Study 3415207 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxalactam (2 g i.v. every 8 h for 5 doses, then 2 g every 12 h)
Number of subjects: 114
Study 3415207 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin (600 mg i.v. every 6 h) plus Gentamicin (1.5 mg/kg i.v. every 8 h)
Number of subjects: 114
Study 3415207 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin plus Gentamicin
Number of subjects: 114
Study 3415207 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxalactam
Number of subjects: 114
Study 29895093 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Refractor simulator
Number of subjects: 24
Study 29895093 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention group
Number of subjects: 24
Study 27703346 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid (ICS)
Number of subjects: 34
Study 27703346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 25215556 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (Z6, n = 616)
Number of subjects: 1233
Study 25215556 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusions (Z3P3, n = 617)
Number of subjects: 1233
Study 25215556 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of treatment after 3 years
Number of subjects: 1233
Study 23590327 — intervention group
Group type: EXPERIMENTAL
Intervention: C-Mill gait adaptability treadmill training (high-intensity, adaptive stepping)
Number of subjects: 126
Study 23590327 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treadmill training (high-intensity, repetitive stepping)
Number of subjects: 126
Study 23590327 — intervention group
Group type: COMPARATOR
Intervention: Usual care physical therapy
Number of subjects: 126
Study 20044162 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine system based on Internet and short message service
Number of subjects: 0
Study 20044162 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 20031551 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 509
Study 20031551 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg
Number of subjects: 509
Study 20031551 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg
Number of subjects: 509
Study 18154091 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil administration during skin plasty operation
Number of subjects: 61
Study 12940804 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of indomethacin, prochlorperazine, and caffeine
Number of subjects: 112
Study 12940804 — intervention group
Group type: COMPARATOR
Intervention: Sumatriptan
Number of subjects: 112
Study 10613779 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatments
Number of subjects: 506
Study 10613779 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 506
Study 10613779 — intervention group
Group type: EXPERIMENTAL
Intervention: Various therapies
Number of subjects: 506
Study 10613779 — intervention group
Group type: EXPERIMENTAL
Intervention: Future RCTs
Number of subjects: 506
Study 9327254 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral medicine intervention (6-week duration)
Number of subjects: 82
Study 9327254 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 82
Study 8447130 — intervention group
Group type: EXPERIMENTAL
Intervention: Drainage
Number of subjects: 80
Study 8447130 — intervention group
Group type: COMPARATOR
Intervention: Nondrainage
Number of subjects: 80
Study 3468098 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg ofloxacin by mouth once daily for ten days
Number of subjects: 30
Study 3468098 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg ofloxacin by mouth twice daily for ten days
Number of subjects: 30
Study 3468098 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitantly administered theophylline
Number of subjects: 30
Study 3468098 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg ofloxacin
Number of subjects: 30
Study 31606860 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 44
Study 31606860 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 44
Study 31606860 — intervention group
Group type: COMPARATOR
Intervention: Control group for HIIT
Number of subjects: 44
Study 31606860 — intervention group
Group type: COMPARATOR
Intervention: Control group for MICT
Number of subjects: 44
Study 29368594 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol and dexmedetomidine
Number of subjects: 84
Study 29368594 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane and dexmedetomidine
Number of subjects: 84
Study 29368594 — intervention group
Group type: COMPARATOR
Intervention: Propofol and normal saline
Number of subjects: 84
Study 29368594 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane and normal saline
Number of subjects: 84
Study 27234663 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly PST (n=1465)
Number of subjects: 2922
Study 27234663 — intervention group
Group type: COMPARATOR
Intervention: Monthly HQACM (n=1457)
Number of subjects: 2922
Study 27234663 — intervention group
Group type: EXPERIMENTAL
Intervention: PST twice weekly (n=118)
Number of subjects: 2922
Study 27234663 — intervention group
Group type: EXPERIMENTAL
Intervention: PST once every 4 weeks (n=116)
Number of subjects: 2922
Study 24295613 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine with 70% alcohol swab sticks for exit-site care and 70% alcohol pads for 'scrub the hubs' in dialysis-related CVC care procedures
Number of subjects: 211
Study 24295613 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 211
Study 22004055 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to CHESS (Comprehensive Health Enhancement Support System)
Number of subjects: 246
Study 22004055 — intervention group
Group type: COMPARATOR
Intervention: Internet access to high-quality lung cancer websites
Number of subjects: 246
Study 20464815 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous altitude changes in +3 Gz
Number of subjects: 2
Study 20464815 — intervention group
Group type: COMPARATOR
Intervention: Continuous altitude changes in +1 Gz
Number of subjects: 2
Study 20464815 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroop task in +3 Gz
Number of subjects: 2
Study 20464815 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task costs
Number of subjects: 2
Study 18514326 — intervention group
Group type: EXPERIMENTAL
Intervention: Remitted substance use disorders (SUDs)
Number of subjects: 0
Study 18514326 — intervention group
Group type: COMPARATOR
Intervention: No remitted substance use disorders (SUDs)
Number of subjects: 0
Study 16279133 — intervention group
Group type: EXPERIMENTAL
Intervention: Active management practices
Number of subjects: 231
Study 16279133 — intervention group
Group type: COMPARATOR
Intervention: Traditional management practices
Number of subjects: 231
Study 14682413 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 400 microg once daily
Number of subjects: 74
Study 14682413 — intervention group
Group type: COMPARATOR
Intervention: Oral montelukast 10 mg once daily
Number of subjects: 74
Study 14682413 — intervention group
Group type: COMPARATOR
Intervention: Sustained-release theophylline 400 mg once daily
Number of subjects: 74
Study 10028204 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaginal Exposure (IE)
Number of subjects: 72
Study 10028204 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 72
Study 8897759 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 million units of IFN-alpha 2b daily for 2 weeks
Number of subjects: 71
Study 8897759 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 million units of IFN-alpha 2b twice a week for 24 weeks
Number of subjects: 71
Study 1516983 — intervention group
Group type: EXPERIMENTAL
Intervention: Embolization of the internal spermatic vein (51 men)
Number of subjects: 137
Study 1516983 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivanissevich technique of high ligation of the spermatic veins (43 men)
Number of subjects: 137
Study 1516983 — intervention group
Group type: COMPARATOR
Intervention: Bernardi technique of high ligation (43 men)
Number of subjects: 137
Study 1516983 — intervention group
Group type: COMPARATOR
Intervention: Control group (Bernardi technique)
Number of subjects: 137
Study 1516983 — intervention group
Group type: COMPARATOR
Intervention: Control group (Ivanissevich technique)
Number of subjects: 137
Study 1516983 — intervention group
Group type: COMPARATOR
Intervention: Control group (Embolization)
Number of subjects: 137
Study 6334456 — intervention group
Group type: EXPERIMENTAL
Intervention: Humidified heated inspired gases at 45 degrees C
Number of subjects: 30
Study 6334456 — intervention group
Group type: COMPARATOR
Intervention: Dry gases at room temperature
Number of subjects: 30
Study 31794566 — intervention group
Group type: EXPERIMENTAL
Intervention: Art Therapy (AT)
Number of subjects: 0
Study 31794566 — intervention group
Group type: COMPARATOR
Intervention: Waiting List (WL)
Number of subjects: 0
Study 30134299 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (0-12 weeks)
Number of subjects: 59
Study 30134299 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise (13-24 weeks)
Number of subjects: 59
Study 30134299 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity exercise (13-24 weeks)
Number of subjects: 59
Study 26356548 — intervention group
Group type: EXPERIMENTAL
Intervention: RPA training (leg-press exercise, twice a week for 6 weeks, 1 or 2 blocks of 5 sets × 5 repetitions with 20 s of passive recovery between sets and 3 min between blocks)
Number of subjects: 22
Study 26356548 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study 25349310 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal Alcohol Syndrome (FAS)
Number of subjects: 70
Study 25349310 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Fetal Alcohol Syndrome (PFAS)
Number of subjects: 70
Study 25349310 — intervention group
Group type: COMPARATOR
Intervention: Alcohol-related neurodevelopmental disorder (ARND)
Number of subjects: 70